Literature DB >> 22422219

The role of serum C-reactive protein in women with lower urinary tract symptoms.

Sheng-Mou Hsiao1, Ho-Hsiung Lin, Hann-Chorng Kuo.   

Abstract

INTRODUCTION AND HYPOTHESIS: Some lower urinary tract dysfunction (LUTD) subtypes may be associated with low-grade inflammation. This study aimed to investigate the role of serum C-reactive protein (CRP) levels in women with lower urinary tract symptoms (LUTS).
METHODS: A total of 197 consecutive women with non-stress urinary incontinence (non-SUI) LUTS and 18 healthy women without LUTS (normal controls) were enrolled. LUTS include urinary storage, voiding, and post-micturition symptoms. Patients with previous bladder or urethral surgery, active urinary tract infections, or possible neurogenic lesions were excluded. Serum CRP levels were measured before any treatment was given. Patients were stratified to LUTD subgroups based on a 3-day voiding diary, uroflowmetry, and selective videourodynamic studies.
RESULTS: Median CRP levels were significantly higher in women with overactive bladder (OAB) wet (i.e., with urgency incontinence, n = 30, 0.12 mg/dl) than those in women with bladder oversensitivity (n = 68, 0.075 mg/dl, P = 0.008) and the control group (0.055 mg/dl, P = 0.032). Further analysis revealed that body mass index and maximum flow rate were two independent factors that affected CRP levels. The area under the receiver-operating characteristic curve for using CRP to predict OAB wet was 0.55, and the most predictive cutoff point for CRP was 0.15 mg/dl (sensitivity 43.5 %, specificity 72.7 %).
CONCLUSIONS: High serum CRP levels were found in women with OAB wet, and they were related to lower maximum urinary flow rates and higher body mass indices in non-SUI LUTD. However, serum CRP is not a suitable biomarker for discriminating between subtypes of non-SUI LUTD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22422219     DOI: 10.1007/s00192-012-1715-1

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  27 in total

1.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

2.  Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder.

Authors:  Joon Jang; Eun Young Park; Seong Il Seo; Tae-Kon Hwang; Joon Chul Kim
Journal:  BJU Int       Date:  2006-08       Impact factor: 5.588

3.  Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis.

Authors:  Man-Jung Hung; Esther Shih-Chu Ho; Pao-Sheng Shen; Mou-Jong Sun; Alex Tong-Long Lin; Gin-Den Chen
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

Review 4.  The phenomenon of the acute phase response.

Authors:  I Kushner
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction.

Authors:  Hann-Chorng Kuo
Journal:  Urology       Date:  2005-11       Impact factor: 2.649

Review 6.  Novel biomarkers for overactive bladder.

Authors:  Rufus Cartwright; Iram Afshan; Alexandros Derpapas; Gopalan Vijaya; Vik Khullar
Journal:  Nat Rev Urol       Date:  2011-02-15       Impact factor: 14.432

7.  Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.

Authors:  Apostolos Apostolidis; Thomas S Jacques; Alex Freeman; Vinay Kalsi; Roshni Popat; Gwendoline Gonzales; Soumendra N Datta; Shabnam Ghazi-Noori; Sohier Elneil; Prokar Dasgupta; Clare J Fowler
Journal:  Eur Urol       Date:  2008-03-07       Impact factor: 20.096

Review 8.  An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.

Authors:  Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer
Journal:  Int Urogynecol J       Date:  2009-11-25       Impact factor: 2.894

9.  Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort.

Authors:  Jennifer L St Sauver; Aruna V Sarma; Debra J Jacobson; Michaela E McGree; Michael M Lieber; Cynthia J Girman; Ajay Nehra; Steven J Jacobsen
Journal:  Am J Epidemiol       Date:  2009-04-24       Impact factor: 4.897

10.  Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity.

Authors:  Hsin-Tzu Liu; Pradeep Tyagi; Michael B Chancellor; Hann-Chorng Kuo
Journal:  BJU Int       Date:  2010-12       Impact factor: 5.588

View more
  15 in total

1.  Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses.

Authors:  Nazema Y Siddiqui; Brian T Helfand; Victor P Andreev; Joseph T Kowalski; Megan S Bradley; H Henry Lai; Mitchell B Berger; Margaret G Mueller; Jennifer A Bickhaus; Vignesh T Packiam; Dee Fenner; Brenda W Gillispie; Ziya Kirkali
Journal:  J Urol       Date:  2019-10-09       Impact factor: 7.450

2.  Urinary Incontinence in Chronic Obstructive Pulmonary Disease: A Common Co-morbidity or a Typical Adverse Effect?

Authors:  Salvatore Battaglia; Alida Benfante; Stefania Principe; Laura Basile; Nicola Scichilone
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

3.  What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013.

Authors:  Christopher H Fry; Arun Sahai; Bahareh Vahabi; Anthony J Kanai; Lori A Birder
Journal:  Neurourol Urodyn       Date:  2014-01-16       Impact factor: 2.696

4.  Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder.

Authors:  G Vijaya; R Cartwright; A Derpapas; P Gallo; R Fernando; V Khullar
Journal:  Int Urogynecol J       Date:  2013-02-02       Impact factor: 2.894

Review 5.  Biomarkers in overactive bladder.

Authors:  Alka A Bhide; Rufus Cartwright; Vik Khullar; G Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2013-01-12       Impact factor: 2.894

6.  Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Shun-Fa Hung; Shiu-Dong Chung; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 7.  Overactive bladder - 18 years - Part I.

Authors:  Jose Carlos Truzzi; Cristiano Mendes Gomes; Carlos A Bezerra; Ivan Mauricio Plata; Jose Campos; Gustavo Luis Garrido; Fernando G Almeida; Marcio Augusto Averbeck; Alexandre Fornari; Anibal Salazar; Arturo Dell'Oro; Caio Cintra; Carlos Alberto Ricetto Sacomani; Juan Pablo Tapia; Eduardo Brambila; Emilio Miguel Longo; Flavio Trigo Rocha; Francisco Coutinho; Gabriel Favre; Jose Antonio Garcia; Juan Castano; Miguel Reyes; Rodrigo Eugenio Leyton; Ruiter Silva Ferreira; Sergio Duran; Vanda Lopez; Ricardo Reges
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

Review 8.  Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links.

Authors:  Q He; Z Wang; G Liu; F Daneshgari; G T MacLennan; S Gupta
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-09-22       Impact factor: 5.554

9.  Symptomatic treatment (using NSAIDS) versus antibiotics in uncomplicated lower urinary tract infection: a meta-analysis and systematic review of randomized controlled trials.

Authors:  Albert Macaire C Ong Lopez; Charles Jeffrey L Tan; Antonio S Yabon; Armin N Masbang
Journal:  BMC Infect Dis       Date:  2021-06-29       Impact factor: 3.090

10.  Medical attendance for lower urinary tract symptoms is associated with subsequent increased risk of outpatient visits and hospitalizations based on a nationwide population-based database.

Authors:  Ming-Ping Wu; Shih-Feng Weng; Ya-Wen Hsu; Jhi-Joung Wang; Hann-Chorng Kuo
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.